AstraZeneca And Ionis ATTR Ambitions Boosted
Efficacy of Eplontersen Maintained For 66 Weeks
Executive Summary
The companies are hoping that new data on recently-filed eplontersen will boost the drug's chances of challenging Alnylam’s Amvuttra and Onpattro.
You may also be interested in...
BridgeBio Comes Back With Positive Phase III Results For Acoramidis In ATTR-CM
The ATTRibute-CM study met its primary endpoint as well as key secondary endpoints, and the company plans to file for US FDA approval before the end of 2023.
AstraZeneca Boosts Rare Disease Pipeline With Ionis Antisense Candidate
AstraZeneca has bulked up its late-stage pipeline with an agreement for Ionis’s eplontersen which is in trials for two rare diseases, quelling some analysts’ fears about the scarcity of catalysts for next year.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.